Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Chia Tai Tianqing Liraglutide vs Victoza in Healthy Subjects
NCT05029076Phase 1Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2019
- Primary completion
- Jun 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liraglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Maximum plasma drug concentration, Time to maximum plasma concentration and 7 more. Started May 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05029076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05029076.